CT引導(dǎo)射頻消融術(shù)在早期肺癌患者中的臨床應(yīng)用效果

打開文本圖片集

Clinical efects CT-guided radirequency ablation in patients with early-stage lungcancer Wang Kunliang"Yan Jin，Yuan Junhua.*horacic DseaseHospital，Zhumdian，

【Abstract】 ObjectiveTo analyze the application efect CT-guided radirequency ablationon early lung cancer.MethodsNinety-eight patients with early-stage lung cancer whoreceived treatment inour hospital from July 2022 to July 2O23 were selectedas theresearchsubjectsand were divided into thecontrol group （n=45）and the observation group （n=53）acording to the numerical ranking tablemethod，and thepatients in thecontrol group underwent conventional treatment，while theobservation group underwent CT-guided radirequency ablation，and the patients the two groups were examined in terms their CDCA5 expresion，survival rate，and recurrnce rate， Tumor markers [alpha-fetoprotein（AFP），carcinoma embryonicantigen （CEA）]，and thediameter tumor foci were compared.ResultsThere was no significant diference in the expression CDCA5 between the two groups before treatment （ P>0.05 ）.After treatment，the expression CDCA5 in the two groups was lower than that before treatment，and the observation group was lower than the control group （ P<0.05 ）.After2 years follow-up，the survivalrate observation group was higher than control group，butthe recurrence rate was lower than control group （ P <0.05）.There was no significant diference in tumor lesion diameter between the two groups before treatment （ P> 0.05），and the tumor lesion diameter the observation group wassmaler than that the control groupafter six months，one year and two years treatment （ P <0.05）.Before treatment， there was no significant difference in the AFP and CEA indexes between the two groups（ P >0.05），and after treatment，the AFP and CEA indexes in the observation group were lower than those in thecontrol group （P<o.o5）.conclusionct-guided radirequency="" ablationin="" early-stage="" lungcancer="" patients="" can="" effectively="" improve="" tumor="" marker="" indicators="" and="" cdca5="" expression，="" survival="" rate，reduce="" recurrencerate，which="" have="" ahighclinicalefecton="" patients'recovery，and="" is="" worthy="" application.=""

肺癌是源于患者氣管、支氣管黏膜、腺體的臨床常見(jiàn)肺部原發(fā)性惡性腫瘤，目前確切病因尚未明確，主要致病因素包括吸煙、職業(yè)暴露、空氣污染、飲食、肺部病史等，早期患者無(wú)顯著癥狀，表現(xiàn)為無(wú)痰或少痰的陣發(fā)性刺激性干咳，隨著病情發(fā)展會(huì)造成患者組織壞死，甚至死亡等，對(duì)患者生命安全造成嚴(yán)重影響[1-3]。（剩余5973字）